Cleerly LABS vs iCAC Device
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if you require a comprehensive, in-depth analysis of coronary CT angiography (CCTA) to precisely detect, quantify, and characterize atherosclerosis and stenosis. This tool is ideal for personalized heart disease management, including tracking disease progression and assessing ischemia, when a dedicated cardiac CT scan is performed or planned.
View Cleerly LABS →Choose iCAC Device if…
Choose iCAC Device if you aim for opportunistic identification and quantification of coronary artery calcium (CAC) from routine, non-contrast, non-gated chest CT scans already performed for other indications. This tool is best suited for early cardiovascular disease detection by leveraging existing imaging data without requiring a dedicated cardiac scan or additional radiation exposure.
View iCAC Device →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | iCAC Device |
|---|---|---|
| Pricing | Per analysis | Contact for pricing |
| Deployment | Cloud-based (AWS), web-based application, with on-site Cleerly Proxy for data transfer. | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly LABSCleerly LABS offers a dedicated, interactive web-based platform with 3D visualization for comprehensive analysis of CCTA data, providing a more direct and engaging user experience. In contrast, iCAC Device primarily integrates into existing PACS/EHR workflows, delivering automated results with visual segmentation, which is less about direct user interaction with the analysis tool itself.
Clinical Value
Cleerly LABSCleerly LABS provides a significantly more comprehensive clinical assessment by characterizing atherosclerosis, quantifying stenosis, and detecting ischemia from CCTA, enabling personalized heart disease management and tracking disease progression over time. iCAC Device, while valuable for opportunistic CAC screening, offers a more limited scope of diagnostic information.
Pricing & Value
Cleerly LABSCleerly LABS offers transparent pricing per analysis, allowing potential users to understand the direct cost, even if it can be substantial. The lack of any public pricing details for iCAC Device makes it impossible to assess its value proposition without direct vendor contact.
Enterprise Readiness
Cleerly LABSCleerly LABS explicitly states both BAA and HIPAA compliance, alongside robust cloud-based deployment and integration capabilities with PACS, RIS, and EHR systems. While iCAC Device also offers strong integration through its Carebricks platform, the lack of explicit BAA and HIPAA compliance details in the provided facts gives Cleerly a slight edge in transparency for enterprise readiness.
Innovation
Cleerly LABSCleerly LABS demonstrates greater innovation by providing a comprehensive, AI-driven platform that not only quantifies and characterizes atherosclerosis and stenosis but also detects ischemia, aiming to redefine heart attack prevention through personalized insights and disease progression tracking. While iCAC Device offers valuable opportunistic CAC detection, Cleerly's detailed plaque phenotyping and integrated ischemia assessment represent a more advanced and holistic approach to cardiovascular risk management.
Support & Docs
Cleerly LABSCleerly LABS explicitly outlines its customer support availability, including specific hours (Monday-Friday, 10 am ET to 6 pm ET) and dedicated channels for technical assistance and IT integration. While Bunkerhill Health's broader Carebricks platform implies enterprise support, the specific details regarding documentation and support for the iCAC Device are less transparent than those provided for Cleerly.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | iCAC Device |
|---|---|---|
| Tool Name | Cleerly LABS | iCAC Device |
| Company | Cleerly | Bunkerhill Health |
| Primary Analysis Target | Detect, quantify, and characterize atherosclerosis and stenosis | Detects and quantifies coronary artery calcium (CAC) |
| Input Scan Type | Coronary CT angiography (CCTA) | Routine, non-contrast, non-gated chest CT scans |
| Key Output/Analysis | Comprehensive coronary plaque assessment (volume, type), stenosis detection and quantification, 3D visualization | Estimates presence and quantity of CAC, exact and four-category quantitative estimates of CAC burden in Agatston units, visual representation of estimated CAC segmentation |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and iCAC Device.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or iCAC Device
Backers
Who funded each tool's parent company.